Craneware Plc (GB:CRW)
LSE:CRW
Top Page
Craneware
(LSE:CRW)
Select Model
Select Model
Rating:61Neutral
Price Target:
1,614.00 p
▼(-27.62% Downside)
Action:ReiteratedDate:02/24/26
The score is driven primarily by solid financial performance (strong margins and a low-debt balance sheet), but it is meaningfully weighed down by weak technical momentum (price below key moving averages with negative MACD) and a relatively high P/E that limits valuation support despite the dividend yield.
Positive Factors
High gross margins
Gross margins above 85% reflect a software-centric cost structure and strong product economics. High gross margins create durable operating leverage, enabling reinvestment in R&D and sales, cushioning profitability versus pricing pressure and supporting long-term margin sustainability.
Negative Factors
Declining free cash flow growth
A recent 13.4% drop in free cash flow growth signals weaker cash generation versus prior periods. If persistent, this reduces capacity to fund organic investment, acquisitions or dividends and may constrain strategic options that support longer-term growth.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Gross margins above 85% reflect a software-centric cost structure and strong product economics. High gross margins create durable operating leverage, enabling reinvestment in R&D and sales, cushioning profitability versus pricing pressure and supporting long-term margin sustainability.
Read all positive factors
Craneware (CRW) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£471.06M
Dividend Yield1.66%
Average Volume (3M)71.71K
Price to Earnings (P/E)22.6
Beta (1Y)0.66
Revenue Growth5.74%
EPS Growth63.23%
CountryUK
Employees747
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.44
Shares Outstanding35,514,107
10 Day Avg. Volume64,377
30 Day Avg. Volume71,707
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)3.07
Price to Sales (P/S)5.04
P/FCF Ratio17.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£2,875.00Price Target Upside28.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.2
Revenue Forecast (FY)£226.01M
Craneware Business Overview & Revenue Model
Company Description
Craneware (CRW) is a leading provider of revenue integrity solutions for the healthcare sector, primarily focusing on optimizing the financial performance of healthcare providers in the United States. The company specializes in software solutions ...
How the Company Makes Money
Craneware generates revenue primarily through subscription-based software licenses, professional services, and ongoing support contracts. The company's key revenue streams include the sale of its software solutions, which are typically offered on ...
Craneware Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Jun 2025 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 211.84M | 205.66M | 189.27M | 165.54M | 75.58M | 71.49M |
| Gross Profit | 165.28M | 179.27M | 162.20M | 142.37M | 70.20M | 66.97M |
| EBITDA | 47.60M | 38.80M | 54.26M | 47.54M | 18.48M | 23.87M |
| Net Income | 22.52M | 19.66M | 11.70M | 9.41M | 12.90M | 16.84M |
Balance Sheet | ||||||
| Total Assets | 525.76M | 551.06M | 543.65M | 568.79M | 311.60M | 115.76M |
| Cash, Cash Equivalents and Short-Term Investments | 40.96M | 55.92M | 34.59M | 47.16M | 235.62M | 47.85M |
| Total Debt | 26.91M | 31.65M | 40.15M | 115.52M | 2.20M | 2.96M |
| Total Liabilities | 186.25M | 213.50M | 215.06M | 235.77M | 51.32M | 47.36M |
| Stockholders Equity | 339.51M | 337.56M | 328.59M | 333.02M | 260.28M | 68.39M |
Cash Flow | ||||||
| Free Cash Flow | 9.69M | 59.41M | 24.91M | 12.93M | 13.21M | 10.96M |
| Operating Cash Flow | 10.10M | 59.90M | 41.86M | 26.96M | 23.54M | 20.67M |
| Investing Cash Flow | -15.94M | -13.98M | -15.81M | -307.32M | -10.32M | -9.71M |
| Financing Cash Flow | -25.44M | -24.58M | -70.00M | 91.90M | 174.55M | -10.72M |
Craneware Technical Analysis
Negative
2230.00
Price Trends
1467.94
Negative
1715.72
Negative
1975.71
Negative
Market Momentum
-47.52
Negative
40.69
Neutral
41.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CRW, the sentiment is Negative. The current price of 2230 is above the 20-day moving average (MA) of 1371.71, above the 50-day MA of 1467.94, and above the 200-day MA of 1975.71, indicating a bearish trend. The MACD of -47.52 indicates Negative momentum. The RSI at 40.69 is Neutral, neither overbought nor oversold. The STOCH value of 41.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CRW.
Craneware Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £38.81M | -13.46 | 10.00% | ― | ― | ― | |
61 Neutral | £471.06M | 22.56 | 6.65% | 1.66% | 5.74% | 63.23% | |
57 Neutral | £130.70M | -5.17 | -3.95% | ― | 31.83% | 46.59% | |
53 Neutral | £197.43M | 41.48 | 1.70% | ― | ― | ― | |
52 Neutral | £17.92M | -3.33 | -58.72% | ― | -30.77% | -6.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £7.30M | -7.18 | -15.57% | ― | 13.32% | 55.07% |
* Healthcare Sector Average
GB:CRW
Craneware
1,340.00
-180.48
-11.87%
GB:COG
Cambridge Cognition Holdings
38.50
5.50
16.67%
GB:IXI
IXICO plc
7.88
0.13
1.61%
GB:KOO
Kooth
107.00
-25.50
-19.25%
GB:DXRX
Diaceutics
154.50
44.50
40.45%
GB:OPT
Optima Health PLC
181.50
13.36
7.95%
Craneware Corporate Events
Business Operations and StrategyStock BuybackDividendsFinancial Disclosures
Craneware Posts Strong Interim Profit Growth and Launches $25m Buyback
Positive
Mar 2, 2026
Craneware reported unaudited interim results for the six months to 31 December 2025 showing solid top-line growth and stronger profitability, with revenue up 6% to $105.7m and double-digit increases in adjusted EBITDA, profit before tax and EPS. A...
Business Operations and StrategyFinancial Disclosures
Craneware Delivers Solid H1 Growth and Cash Generation Despite US Rebate Programme Disruption
Positive
Jan 20, 2026
Craneware reported a solid first half for FY26, with revenue for the six months to 31 December 2025 rising 6% year-on-year to about $106m and adjusted EBITDA growing at a double-digit rate to roughly $33.4m, supported by sustained demand across it...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.